Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on Linkedin:
“A pioneer in APS testing, Prof. Pier Luigi Meroni delivered a powerful message at ISTH 2026 in Paris yesterday: what do we really target with our aPL assays?
His update on harmonizing ELISA and non‑ELISA antiphospholipid antibody tests with new commutable reference material for anti‑β2GPI and aCL IgG showed that standardization of units is possible—but that variability from assay design and antibody heterogeneity remains.
For me, the key takeaway was a clear shift from ‘any aPL positive’ towards biologically meaningful β2GPI‑dependent specificities and domain reactivity, which should drive future APS risk stratification, classification, and guidelines.
But how ready are our routine laboratories to embrace this more targeted, domain‑focused approach to APS testing?”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026
-
Jul 12, 2026, 06:45Brian O Mahony: Advancing Concizumab Therapy for Hemophilia With Inhibitors at ISTH 2026
-
Jul 12, 2026, 06:42PERT-Guided Patient Selection for Advanced Pulmonary Embolism Therapies
-
Jul 12, 2026, 06:12Precision in Antithrombotic Therapy at ISTH 2026 – The Lancet Haematology
-
Jul 11, 2026, 23:36Emmanuel J Favaloro: A Fresh Perspective on the Manual Tilt Tube Method for PT and INR Determination
-
Jul 11, 2026, 21:47Michelle Meyer: Working Together to Advance Stroke Prevention in Atrial Fibrillation
-
Jul 11, 2026, 21:44Timos Papagatsias: From Promising Concepts to Clinical Differentiation at ISTH 2026